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Catastrophic Antiphospholipid Syndrome
Gabriel Hocum, DO and Jeff Youker, MD
Providence St. Vincent, Internal Medicine Residency, Portland, Oregon

INTRODUCTION

BRAIN MRI

Catastrophic Antiphospholipid Syndrome (CAPS) is a rare and
extreme manifestation of Antiphospholipid Syndrome (APS)
that features widespread thrombotic disease affecting
multiple small vessels in a short time frame. CAPS affects only
0.8% of APS patients, but when it occurs it is has a mortality
rate of approximately 50%.
CASE REPORT

A 50 year old female with SLE and APS presented with 1 month
of cough and fatigue and 2 days of severe confusion after
missing doses of rivaroxaban. In the ED she was intubated for
airway protection and transferred to the ICU.
Her evaluation revealed multi-organ failure with extensive
subacute brain infarcts, NSTEMI, severe heart failure, acute
kidney injury, and acute on chronic anemia and
thrombocytopenia. Her brain lesions were randomly
distributed and could not be explained by a typical
cardioemobolic phenomenon or global hypo-perfusion. Lab
work revealed decreased C3 and C4, and increased anticardiolipin and anti-B2-glycoprotein antibodies.
She was diagnosed with probable CAPS based on clinical
criteria, and treated with high dose steroids, anticoagulation
and IVIG. Her acuity prevented histopathologic confirmation of
small vessel occlusion. Despite some signs of clinical
improvement and successful prevention of further thrombotic
events, she had sustained extensive irreversible neurologic
damage and was transitioned to comfort care.
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Extensive subacute infarctions with associated petechial hemorrhage throughout the cerebral hemispheres and cerebellum

DISCUSSION

Most of our understanding of this condition comes from retrospective analyses of patients in
the “CAPS Registry”, which in 2016 included about 500 patients. It is more common in
women, and the average age of onset is 38. 60% of these patients had an underlying primary
diagnosis of APS; 30% had an associated SLE diagnosis; 65% of cases had an identifiable
antecedent, most commonly, infection.
Diagnostic Criteria:
1. Involvement of three or more organs, systems, and/or tissues
2. Development of manifestations simultaneously or in less than a week
3. Presence of antiphospholipid antibodies
4. Histopathologic evidence of small vessel occlusion in at least one organ or tissue
Treatment:
1. Treatment of the inciting factor if one is identifiable (e.g. antibiotics for bacterial infection)
2. Anticoagulation, usually with heparin
3. High dose intravenous steroids
4. Plasma exchange and/or IVIG
5. Other considerations: cyclophosphamide, rituximab, eculizumab
This case highlights the severity of the CAPS disease process, and the importance of early
recognition and aggressive management. The primary prognostic factor for this patient,
however, was not prompt diagnosis or treatment, but the extent of irreversible damage at
the time of presentation.

